Effects of Patiromer on Pharmacokinetics of Immunosuppresive Drugs in Renal Transplant Recipients
Status:
Not yet recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
Patiromer lowers potassium effectively in patients with hyperkalemia and chronic kidney
disease. Patients with a kidney transplant usually have reduced renal function and may also
develop hyperkalemia. However, potential interactions between immunosuppressive medications
and patiromer have not been evaluated. These interactions could involve change in AUC of
immunosuppressive drugs, such as calcineurin inhibitors or mycophenolate, or increased risk
of hypomagnesemia, since both tacrolimus and patiromer have this potential side effect. We
wish to evaluate potential interactions to ensure safe use of this drug in the transplant
population.